Schinazi et al. patent 5,631,128, patent 5,650,268, patent 5,856,086 et patent 6,503,705 | :: ABL, SA :: HIV Clinical Point of Care Software :: TherapyEdge®-HIV :: ViroScore® Suite :: MyView

Schinazi et al. patent 5,631,128, patent 5,650,268, patent 5,856,086 et patent 6,503,705

Advanced Biological Laboratories (ABL) SA, a Luxembourg-based company developing personalized medicine IT systems in the fields of infectious disease, is pleased to announce an exclusive and global license agreement with Emory University (Atlanta, Georgia) for the commercialization of a novel HIV-1 reverse transcriptase codon deletion and in all fields of use, including the management of HIV infections. Financial terms were not disclosed.ABL with this new licensing agreement continue strengthening its patent estate which is covering computational systems for personalized medicine in the field of chronic diseases such as, but not limited to, HIV/AIDS, liver diseases and affective disorders.
International Publication
http://www.emory.edu/home/index.html